Alexion Pharmaceuticals (NASDAQ:ALXN): The mean short term price target for Alexion Pharmaceuticals (NASDAQ:ALXN) has been established at $193.47 per share. The higher price target estimate is at $221 and the lower price target estimate is expected at $145 according to 15 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $24.47
Many analysts have stated their opinion on the company shares. Equity Analysts at the Morgan Stanley maintains the rating on Alexion Pharmaceuticals (NASDAQ:ALXN). The brokerage firm has issued a Overweight rating on the shares. The Analysts at the ratings agency lowers the price target from $203 per share to $189 per share. The rating by the firm was issued on June 7, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, Mackay Martin, officer (EVP & Global Head of R&D) of Alexion Pharmaceuticals Inc, unloaded 4,097 shares at an average price of $139.81 on May 16, 2016. The total amount of the transaction was worth $572,802, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Alexion Pharmaceuticals (NASDAQ:ALXN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 2.29 points or 1.69% at $133.32 with 1,653,974 shares getting traded. Post opening the session at $135.72, the shares hit an intraday low of $133.18 and an intraday high of $137.63 and the price was in this range throughout the day. The company has a market cap of $29,866 million and the number of outstanding shares have been calculated to be 224,020,160 shares. The 52-week high of Alexion Pharmaceuticals (NASDAQ:ALXN) is $208.88 and the 52-week low is $124.16.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.